Clinical, Imaging, and Laboratory Markers of Premanifest Spinocerebellar Ataxia 1, 2, 3, and 6: A Systematic Review

키워드

참고문헌 (93)

1. Parodi L, "Hereditary ataxias and paraparesias : clinical and genetic update", Curr Opin Neurol, 31, pp.462~471 (2018)
2. Thomas EA, "Involvement of HDAC1 and HDAC3 in the pathology of polyglutamine disorders: therapeutic implications for selective HDAC1", HDAC3 inhibitors, 2014, pp.7, 634~661
3. Schöls L, "Autosomal dominant cerebellar ataxias : clinical features, genetics, and pathogenesis", Lancet Neurol, 3, pp.291~304 (2004)
4. Paulson H, "Ataxia and hereditary disorders", Neurol Clin, 19, pp.759~782 (2001)
5. Rüb U, "Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7", Prog Neurobiol, 104, pp.38~66 (2013)
6. Kim HJ, "SCA in Korea and its regional distribution : a multicenter analysis", Parkinsonism Relat Disord, 17, pp.72~75 (2011)
7. Lee WY, "Frequency analysis and clinical characterization of spinocerebellar ataxia types 1, 2, 3, 6, and 7 in Korean patients", Arch Neurol, 60, pp.858~863 (2003)
8. Jin DK, "Frequency of spinocerebellar ataxia types 1, 2, 3, 6, 7 and dentatorubral pallidoluysian atrophy mutations in Korean patients with spinocerebellar ataxia", J Neurol, 246, pp.207~210 (1999)
9. Sullivan R, "Spinocerebellar ataxia : an update", J Neurol, 266, pp.533~544 (2019)
10. Klockgether T, "Milestones in ataxia", Mov Disord, 26, pp.1134~1141 (2011)
11. Okazawa H, "Interaction between mutant ataxin-1 and PQBP-1 affects transcription and cell death", Neuron, 34, pp.701~713 (2002)
12. La Spada AR, "Polyglutamine-expanded ataxin-7 antagonizes CRX function and induces cone-rod dystrophy in a mouse model of SCA7", Neuron, 31, pp.913~927 (2001)
13. Matilla A, "The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1", Nature, 389, pp.974~978 (1997)
14. Klockgether T, "Spinocerebellar ataxia", Nat Rev Dis Primers, 5, pp.24~ (2019)
15. van de Warrenburg BP, "Age at onset variance analysis in spinocerebellar ataxias : a study in a Dutch-French cohort", Ann Neurol, 57, pp.505~512 (2005)
16. Kim JY, "Molecular analysis of spinocerebellar ataxias in Koreans : frequencies and reference ranges of SCA1, SCA2, SCA3, SCA6, and SCA7", Mol Cells, 12, pp.336~341 (2001)
17. Maas RP, "The preclinical stage of spinocerebellar ataxias", Neurology, 85, pp.96~103 (2015)
18. Schmitz-Hübsch T, "Scale for the assessment and rating of ataxia : development of a new clinical scale", Neurology, 66, pp.1717~1720 (2006)
19. Lima M, "Towards the identification of molecular biomarkers of spinocerebellar ataxia type 3(SCA3)", Machado-Joseph disease(MJD), 2018, pp.1049, 309~319
20. da Silva Carvalho G, "Cytokines in Machado Joseph disease", spinocerebellar ataxia 3, 2016, pp.15, 518~525
21. Jacobi H, "Inventory of Non-Ataxia Signs(INAS) : validation of a new clinical assessment instrument", Cerebellum, 12, pp.418~428 (2013)
22. Pearson CE, "Repeat instability : mechanisms of dynamic mutations", Nat Rev Genet, 6, pp.729~742 (2005)
23. Stevanin G, "Clinical and molecular advances in autosomal dominant cerebellar ataxias : from genotype to phenotype and physiopathology", Eur J Hum Genet, 8, pp.4~18 (2000)
24. Globas C, "Early symptoms in spinocerebellar ataxia type 1, 2, 3, and 6", Mov Disord, 23, pp.2232~2238 (2008)
25. Velázquez-Pérez LC, "Spinocerebellar ataxia type 2 : clinicogenetic aspects, mechanistic insights, and management approaches", Front Neurol, 8, pp.472~ (2017)
26. Velázquez-Pérez L, "Progression of early features of spinocerebellar ataxia type 2 in individuals at risk : a longitudinal study", Lancet Neurol, 13, pp.482~489 (2014)
27. Chen JW, "Clinical characteristics, radiological features and gene mutation in 10 Chinese families with spinocerebellar ataxias", Chin Med J(Engl), 128, pp.1714~1723 (2015)
28. Raposo M, "Nystagmus as an early ocular alteration in Machado-Joseph disease(MJD", SCA3), 2014, pp.14, 17~
29. Mizushima K, "Analysis of spinocerebellar ataxia type 2 in Gunma Prefecture in Japan : CAG trinucleotide expansion and clinical characteristics", J Neurol Sci, 156, pp.180~185 (1998)
30. Martin J, "Spinocerebellar ataxia type 7(SCA7)-correlations between phenotype and genotype in one large Belgian family", J Neurol Sci, 168, pp.37~46 (1999)
31. Cancel G, "Molecular and clinical correlations in spinocerebellar ataxia 2 : a study of 32 families", Hum Mol Genet, 6, pp.709~715 (1997)
32. Tezenas du Montcel S, "Prediction of the age at onset in spinocerebellar ataxia type 1, 2, 3 and 6", J Med Genet, 51, pp.479~486 (2014)
33. Dziedzic T, "Biochemical and radiological markers of Alzheimer’s disease progression", J Alzheimers Dis, 50, pp.623~644 (2016)
34. Braak H, "Staging of brain pathology related to sporadic Parkinson’s disease", Neurobiol Aging, 24, pp.197~211 (2003)
35. Burciu RG, "Progression marker of Parkinson’s disease : a 4-year multi-site imaging study", Brain, 140, pp.2183~2192 (2017)
36. Yang J, "Longitudinal progression markers of Parkinson’s disease : current view on structural imaging", Curr Neurol Neurosci Rep, 18, pp.83~ (2018)
37. Odish OFF, "EEG may serve as a biomarker in Huntington’s disease using machine learning automatic classification", Sci Rep, 8, pp.16090~ (2018)
38. Scarabino D, "Leukocyte telomere shortening in Huntington’s disease", J Neurol Sci, 396, pp.25~29 (2019)
39. Wijeratne PA, "An image-based model of brain volume biomarker changes in Huntington’s disease", Ann Clin Transl Neurol, 5, pp.570~582 (2018)
40. Jędrak P, "Mitochondrial alterations accompanied by oxidative stress conditions in skin fibroblasts of Huntington’s disease patients", Metab Brain Dis, 33, pp.2005~2017 (2018)
41. Fazio P, "Novel imaging biomarkers for Huntington’s disease and other hereditary choreas", Curr Neurol Neurosci Rep, 18, pp.85~ (2018)
42. Jacobi H, "Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study : analysis of baseline data", Lancet Neurol, 12, pp.650~658 (2013)
43. Velázquez-Pérez L, "Comprehensive study of early features in spinocerebellar ataxia 2 : delineating the prodromal stage of the disease", Cerebellum, 13, pp.568~579 (2014)
44. Velázquez-Pérez L, "Abnormal corticospinal tract function and motor cortex excitability in non-ataxic SCA2mutation carriers : a TMS study", Clin Neurophysiol, 127, pp.2713~2719 (2016)
45. Park H, "Parkinsonism in spinocerebellar ataxia", Biomed Res Int, 2015, pp.125273~ (2015)
46. Lindsay E, "Cognitive changes in the spinocerebellar ataxias due to expanded polyglutamine tracts : a survey of the literature", Brain Sci, 7, pp.83~ (2017)
47. Velázquez-Pérez L, "Saccade velocity is reduced in presymptomatic spinocerebellar ataxia type 2", Clin Neurophysiol, 120, pp.632~635 (2009)
48. Wu C, "Oculomotor deficits in spinocerebellar ataxia type 3 : potential biomarkers of preclinical detection and disease progression", CNS Neurosci Ther, 23, pp.321~328 (2017)
49. Christova P, "Impaired eye movements in presymptomatic spinocerebellar ataxia type 6", Arch Neurol, 65, pp.530~536 (2008)
50. Farrar MA, "Motor cortical dysfunction develops in spinocerebellar ataxia type 3", Clin Neurophysiol, 127, pp.3418~3424 (2016)
51. "Rev Neurol", 1998, 955~963
52. Velázquez Pérez L, "Electrophysiological features in patients and presymptomatic relatives with spinocerebellar ataxia type 2", J Neurol Sci, 263, pp.158~164 (2007)
53. Velázquez-Pérez L, "Early corticospinal tract damage in prodromal SCA2 revealed by EEG-EMG and EMG-EMG coherence", Clin Neurophysiol, 128, pp.2493~2502 (2017)
54. Rezende TJR, "Structural signature of SCA3 : from presymptomatic to late disease stages", Ann Neurol, 84, pp.401~408 (2018)
55. Reetz K, "Brain atrophy measures in preclinical and manifest spinocerebellar ataxia type 2", Ann Clin Transl Neurol, 5, pp.128~137 (2018)
56. Wu X, "Microstructural alterations in asymptomatic and symptomatic patients with spinocerebellar ataxia type 3 : a tract-based spatial statistics study", Front Neurol, 8, pp.714~ (2017)
57. Falcon MI, "Early cerebellar network shifting in spinocerebellar ataxia type 6", Cereb Cortex, 26, pp.3205~3218 (2016)
58. Mascalchi M, "Proton magnetic resonance spectroscopy in an Italian family with spinocerebellar ataxia type 1", Ann Neurol, 43, pp.244~252 (1998)
59. Li QF, "Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3", Mol Neurodegener, 14, pp.39~ (2019)
60. Raposo M, "Accumulation of mitochondrial DNA common deletion since the preataxic stage of Machado-Joseph disease", Mol Neurobiol, 56, pp.119~124 (2019)
61. de Assis AM, "Peripheral oxidative stress biomarkers in spinocerebellar ataxia type 3", Machado-Joseph disease, 2017, pp.8, 485~
62. Nanetti L, "Stance instability in preclinical SCA1 mutation carriers : a 4-year prospective posturography study", Gait Posture, 57, pp.11~14 (2017)
63. Velázquez-Pérez L, "Postural instability in prodromal spinocerebellar ataxia type 2 : insights into cerebellar involvement before onset of permanent ataxia", Cerebellum, 16, pp.279~281 (2017)
64. Rochester L, "Gait impairment precedes clinical symptoms in spinocerebellar ataxia type 6", Mov Disord, 29, pp.252~255 (2014)
65. Ilg W, "Individual changes in preclinical spinocerebellar ataxia identified via increased motor complexity", Mov Disord, 31, pp.1891~1900 (2016)
66. Ilg W, "Specific influences of cerebellar dysfunctions on gait", Brain, 130(Pt 3), pp.786~798 (2007)
67. Rodríguez-Labrada R, "Subtle rapid eye movement sleep abnormalities in presymptomatic spinocerebellar ataxia type 2 gene carriers", Mov Disord, 26, pp.347~350 (2011)
68. Rodríguez-Labrada R, "Sleep spindles and K-complex activities are decreased in spinocerebellar ataxia type 2 : relationship to memory and motor performances", Sleep Med, 60, pp.188~196 (2019)
69. Visser M, "Assessment of autonomic dysfunction in Parkinson’s disease : the SCOPA-AUT", Mov Disord, 19, pp.1306~1312 (2004)
70. Montes BJ, "Disautonomic features in presyntomatic subjects and patients with type 2 spinocerebellar ataxia", Rev Mex Neuroci, 12, pp.76~81 (2011)
71. Montes-Brown J, "Autonomic dysfunction in presymptomatic spinocerebellar ataxia type-2", Acta Neurol Scand, 125, pp.24~29 (2012)
72. du Montcel ST, "Composite cerebellar functional severity score : validation of a quantitative score of cerebellar impairment", Brain, 131(Pt 5), pp.1352~1361 (2008)
73. Schmitz-Hübsch T, "SCA Functional Index : a useful compound performance measure for spinocerebellar ataxia", Neurology, 71, pp.486~492 (2008)
74. Yang ZH, "Metabolic profiling reveals biochemical pathways and potential biomarkers of spinocerebellar ataxia 3", Front Mol Neurosci, 12, pp.159~ (2019)
75. van Gaalen J, "Abnormal eyeblink conditioning is an early marker of cerebellar dysfunction in preclinical SCA3 mutation carriers", Exp Brain Res, 237, pp.427~433 (2019)
76. Velázquez-Perez L, "Motor decline in clinically presymptomatic spinocerebellar ataxia type 2 gene carriers", PLoS One, 4, pp.e5398~ (2009)
77. Velázquez-Perez L, "Progression markers of Spinocerebellar ataxia 2. A twenty years neurophysiological follow up study", J Neurol Sci, 290, pp.22~26 (2010)
78. Velázquez-Pérez L, "A comprehensive review of spinocerebellar ataxia type 2 in Cuba", Cerebellum, 10, pp.184~198 (2011)
79. Velázquez-Pérez L, "Prodromal spinocerebellar ataxia type 2 : prospects for early interventions and ethical challenges", Mov Disord, 32, pp.708~718 (2017)
80. Velázquez-Pérez L, "Central motor conduction time as prodromal biomarker in spinocerebellar ataxia type 2", Mov Disord, 31, pp.603~604 (2016)
81. Velázquez-Pérez L, "Progression of corticospinal tract dysfunction in pre-ataxic spinocerebellar ataxia type 2 : a two-years follow-up TMS study", Clin Neurophysiol, 129, pp.895~900 (2018)
82. Rodríguez-Díaz JC, "Neurorehabilitation therapy in spinocerebellar ataxia type 2 : a 24-week, rater-blinded, randomized, controlled trial", Mov Disord, 33, pp.1481~1487 (2018)
83. Morlet É, "Neuroprotective effects of lithium : what are the implications in humans with neurodegenerative disorders?", Geriatr Psychol Neuropsychiatr Vieil, 16, pp.78~86 (2018)
84. Duarte-Silva S, "Pharmacological therapies for Machado-Joseph disease", Adv Exp Med Biol, 1049, pp.369~394 (2018)
85. Saute JAM, "Planning future clinical trials for Machado-Joseph disease", Adv Exp Med Biol, 1049, pp.321~348 (2018)
86. Rubinsztein DC, "Diminishing return for mechanistic therapeutics with neurodegenerative disease duration? : there may be a point in the course of a neurodegenerative condition where therapeutics targeting disease-causing mechanisms are futile", Bioessays, 38, pp.977~980 (2016)
87. Keiser MS, "Gene suppression strategies for dominantly inherited neurodegenerative diseases : lessons from Huntington’s disease and spinocerebellar ataxia", Hum Mol Genet, 25(R1), pp.R53~ (2016)
88. Li X, "Toward therapeutic targets for SCA3 : insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance", Prog Neurobiol, 132, pp.34~58 (2015)
89. Yi J, "Sodium valproate alleviates neurodegeneration in SCA3", MJD via suppressing apoptosis and rescuing the hypoacetylation levels of histone H3 and H4, 2013, pp.8, e54792~
90. Matilla-Dueñas A, "Handbook of the cerebellum and cerebellar disorders", pp.2370~2394 (2013), Springer
91. Watson LM, "Polyglutamine disease : from pathogenesis to therapy", S Afr Med J, 102, pp.481~484 (2012)
92. Almaguer-Mederos LE, "Estimation of the age at onset in spinocerebellar ataxia type 2 Cuban patients by survival analysis", Clin Genet, 78, pp.169~174 (2010)
93. Liberati A, "The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration", BMJ, 339, pp.b2700~ (2009)

관련 논문AI추천